New and updated data for genentech's fixed-duration columvi and lunsumio at ash 2024 reinforce their potential to improve outcomes for people with lymphoma

South san francisco, calif.--(business wire)--genentech, a member of the roche group (six: ro, rog; otcqx: rhhby), announced today that new and updated data from its industry-leading cd20xcd3 t-cell-engaging bispecific antibody program were presented at the 66th american society of hematology (ash) annual meeting & exposition, december 7-10, 2024. with more than 20 bispecific antibody abstracts accepted for presentation, data showcase the benefits of fixed-duration columvi® (glofitamab-gxbm.
ASH Ratings Summary
ASH Quant Ranking